loading page

Activation of anti-SARS-CoV-2 human CTLs by extracellular vesicles engineered with the N viral protein
  • +4
  • Francesco Manfredi,
  • Chiara Chiozzini,
  • Flavia Ferrantelli,
  • Patrizia Leone,
  • Andrea Giovannelli,
  • Massimo Sanchez,
  • Maurizio Federico
Francesco Manfredi
Istituto Superiore di Sanita
Author Profile
Chiara Chiozzini
Author Profile
Flavia Ferrantelli
Author Profile
Patrizia Leone
Author Profile
Andrea Giovannelli
Istituto Superiore di Sanita
Author Profile
Massimo Sanchez
Istituto Superiore di Sanita
Author Profile
Maurizio Federico
Istituto Superiore di Sanità
Author Profile


We investigated an innovative anti-SARS-CoV-2 immune strategy finalized to oral administration of extracellular vesicles (EVs) inducing an anti-SARS-CoV-2 N CD8+ T cytotoxic lymphocyte (CTL) immune response. We previously reported that the SARS-CoV-2 N protein can be uploaded at high levels in EVs upon fusion with Nefmut, i.e., a biologically inactive HIV-1 Nef mutant incorporating into EVs at quite high levels. Here, we analyze the immunogenic properties in human cells of EVs engineered with SARS-CoV-2 N fused at the C-terminus of either Nefmut or a deletion mutant of Nefmut referred to as NefmutPL. Analysis of in vitro produced EVs proven the uploading of N protein also when fused with truncated Nefmut. Mice injected with DNA vectors expressing each fusion protein developed robust SARS-CoV-2 N-specific CD8+ T cell immune responses. When ex vivo human dendritic cells were challenged with EVs engineered with either fusion products, the induction of a robust N-specific CTL activity, as evaluated by both CD107a and trogocytosis assays, was observed. Through these data we achieved the proof-of-principle that engineered EVs can be instrumental to elicit anti-SARS-CoV-2 CTL immune response in human cells. This achievement represents a mandatory step towards the upcoming experimentations in pre-clinical models.

Peer review status:UNDER REVIEW

04 Nov 2021Submitted to Biotechnology Journal
05 Nov 2021Assigned to Editor
05 Nov 2021Submission Checks Completed
15 Nov 2021Reviewer(s) Assigned